Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
(2015) In Cancer 121(21). p.3853-3861- Abstract
- The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7749443
- author
- Rathkopf, Dana E ; Larson, Steven M ; Anand, Aseem LU ; Morris, Michael J ; Slovin, Susan F ; Shaffer, David R ; Heller, Glenn ; Carver, Brett ; Rosen, Neal and Scher, Howard I
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer
- volume
- 121
- issue
- 21
- pages
- 3853 - 3861
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:26178426
- wos:000363262100016
- scopus:84944768819
- pmid:26178426
- ISSN
- 1097-0142
- DOI
- 10.1002/cncr.29578
- language
- English
- LU publication?
- yes
- id
- 4c5f3dbc-1bd0-459e-89d1-c90787e1708d (old id 7749443)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26178426?dopt=Abstract
- date added to LUP
- 2016-04-01 09:48:24
- date last changed
- 2022-02-02 02:58:47
@article{4c5f3dbc-1bd0-459e-89d1-c90787e1708d,
abstract = {{The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).}},
author = {{Rathkopf, Dana E and Larson, Steven M and Anand, Aseem and Morris, Michael J and Slovin, Susan F and Shaffer, David R and Heller, Glenn and Carver, Brett and Rosen, Neal and Scher, Howard I}},
issn = {{1097-0142}},
language = {{eng}},
number = {{21}},
pages = {{3853--3861}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Cancer}},
title = {{Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.}},
url = {{http://dx.doi.org/10.1002/cncr.29578}},
doi = {{10.1002/cncr.29578}},
volume = {{121}},
year = {{2015}},
}